DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) $ in Millions			12 Months Ended
	Feb. 14, 2024	Dec. 31, 2021 segment	Dec. 31, 2023 USD ($) segment facility	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Feb. 16, 2024 CAD ($)	Feb. 16, 2024 USD ($)
Class of Stock [Line Items]
Number of pharmaceutical manufacturing facilities | facility			3
FDIC guaranteed amount			$ 250,000
Impairment loss related to property and equipment recognized			0	$ 0	$ 0
Assets held for sale			8,020,000	8,020,000
Intangible asset impairment charge			$ 0	112,000	2,374,000
Number of operating segments | segment			2
Number of segments | segment		1	2
Goodwill, impairment loss			$ 0	0	$ 0
Disposal Group, Held-for-Sale, Not Discontinued Operations | Oakville, Ontario Former Manufacturing Facility | Subsequent Event
Class of Stock [Line Items]
Consideration						$ 19.2	$ 14,200,000
Performance Shares
Class of Stock [Line Items]
Vesting period			3 years
Performance Shares | Subsequent Event
Class of Stock [Line Items]
Vesting period	3 years
Minimum
Class of Stock [Line Items]
Useful life			7 years
Maximum
Class of Stock [Line Items]
Useful life			10 years
Canada
Class of Stock [Line Items]
Assets held for sale			$ 8,000,000	8,000,000
Cranford Pharmaceuticals
Class of Stock [Line Items]
Funds held in escrow for asset purchase				$ 5,000,000